Welcome to our dedicated page for Avalon GloboCare SEC filings (Ticker: ALBT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avalon GloboCare Corp. filings document public-company disclosures for its consumer diagnostics, generative AI software, intellectual property, and capital structure. Recent 8-K reports cover material events involving Avalon Quantum AI LLC, the Catch-Up AI video platform, Nasdaq listing-compliance notices, shareholder communications, and pro forma financial information tied to the completed sale of Avalon RT 9 Properties, LLC.
The company’s proxy and registration filings describe board elections, auditor ratification, equity incentive-plan matters, advisory compensation votes, Nasdaq-rule approvals for warrant share issuance, and securities registration matters. Avalon’s filings also address common stock, warrants, pre-funded warrants, shareholder voting mechanics, governance procedures, operating and financial results, and risk disclosures for a smaller reporting company.
Avalon GloboCare Corp. reported that Nasdaq has again found it out of compliance with the Nasdaq Capital Market’s continued listing standards due to low stockholders’ equity and related criteria. Nasdaq previously notified the company that its stockholders’ equity was a deficit of $3,891,270 as of the quarter ended March 31, 2025, below the required minimum equity of $2,500,000, and that it did not meet alternative market value or net income standards.
Nasdaq had granted Avalon GloboCare up to 180 days from May 22, 2025, through November 18, 2025, to regain compliance. On November 19, 2025, Nasdaq sent a new notice stating the company remains non‑compliant and that its common stock is subject to suspension and delisting unless it requests a hearing. Avalon GloboCare plans to request a hearing before a Nasdaq Hearings Panel, which will automatically stay any suspension or delisting while the hearing process and any Panel‑granted extension period are ongoing.
Avalon GloboCare Corp. filed a current report to share that it has updated its investor presentation, which may be used in meetings with investors and analysts. The presentation includes additional information about YOOV Group Holding Limited and certain preliminary financial data for YOOV in connection with their previously announced proposed merger, under which YOOV would become a wholly owned direct subsidiary of Avalon GloboCare.
The filing stresses that YOOV’s preliminary figures are prepared by YOOV management, have not been audited or reviewed by its independent public accounting firm, and may change when YOOV’s audited results for the year ended March 31, 2025 are finalized. The report also highlights that the merger remains subject to conditions such as stockholder approval and other closing requirements, points investors to the Form S-4 registration statement and proxy statement/prospectus filed with the SEC for detailed information, and includes extensive forward-looking statement and risk disclosures related to the proposed merger.
Avalon GloboCare Corp. filed an amended current report to clarify details of a financing agreement, a senior secured promissory note, and related preferred stock terms.
The company agreed to sell 141,643 shares of common stock for $500,000, or $3.53 per share, to York Sun Investment Holding Limited under a securities purchase agreement. It also entered into a waiver with Mast Hill Fund, L.P. under a $2,845,000 senior secured promissory note, under which the holder waived potential cash penalties tied to a prior issuance of Series C preferred stock but retained dilutive adjustment rights, subject to a $1.00 per-share floor price.
Based on principal, accrued, and estimated future interest, the report states that, at the floor price, the note could be converted into approximately 2,942,041 common shares, subject to a 4.99% beneficial ownership limit. Separately, the Series C preferred stock designation was amended to reduce its beneficial ownership limit from 19.99% to 4.99%, further constraining how much any holder can own through conversion.
Avalon GloboCare Corp. filed a current report describing a planned product launch. The company announced that it intends to begin selling its KetoAir™ breathalyzer device in the United Kingdom starting on September 1, 2025. This step represents an international rollout of the KetoAir™ product beyond existing markets. The announcement was made through a press release that is included as an exhibit and is referenced for further details on the planned UK introduction.
Avalon GloboCare Corp. (ALBT) reported continued operating losses and significant balance sheet activity in the six months ended June 30, 2025. The company recorded recurring net losses of approximately $15.94 million for the six-month period and generated negative operating cash flow of about $3.03 million. During Q1 2025 Avalon completed the redemption of its 40% equity interest in Lab Services MSO for aggregate cash of $1.745 million and the surrender of Series B preferred stock (carrying value $11.0 million), recognizing an increase to additional paid-in capital of $2.3487 million. The company recorded a $9.0766 million loss on extinguishment of debt related to modification/waiver of the June 2024 convertible note financing. Derivative liabilities declined, producing a fair value gain of $446,816 for the six months. The company wrote off and reserved for credit losses ($1.65 million) and reported material warrant and convertible instruments, including the June 2024 convertible note (principal $2.845 million). Avalon’s laboratory services segment ceased upon the Lab Services MSO redemption; the real property segment remains operational.
Avalon GloboCare Corp. issued 221,000 shares of unregistered common stock to a noteholder upon partial conversions of an outstanding promissory note between July 30, 2025 and August 6, 2025. After these issuances the company reported 3,690,109 shares outstanding as of August 6, 2025. The filing states the shares were not registered under the Securities Act and were offered in reliance on the Section 4(a)(2) exemption.
The disclosure provides the exact share amount and updated share count but contains no details on the promissory note balance converted, the conversion price, or any cash impacts. The information is factual and narrow in scope, limited to the share issuance and the registration exemption relied upon.
Avalon GloboCare Corp. (Nasdaq: ALBT) filed a Form 8-K dated 28 Jul 2025 to disclose that its wholly-owned subsidiary, Q&A Distribution, LLC, has entered a distribution agreement with Saga Health Corporation for the KetoAir™ breathalyzer device. The filing is made under Item 7.01 (Reg FD) and includes the related press release as Exhibit 99.1.
No financial terms, volume commitments or revenue projections were provided. Management expressly states the information is furnished, not filed, thereby avoiding automatic incorporation into other SEC documents. While the agreement could broaden ALBT’s presence in the metabolic health diagnostics market, investors have insufficient data to quantify potential sales or profitability impact. No other material events, financial statements, or pro-forma data accompany this report.